| Literature DB >> 27278404 |
Eduardo Samo Gudo1, Gabriela Pinto2, Jacqueline Weyer3, Chantel le Roux3, Arcildo Mandlaze2, Américo Feriano José2, Argentina Muianga2, Janusz Tadeusz Paweska3,4.
Abstract
BACKGROUND: Rift Valley fever virus (RVFV) remains heavily neglected in humans in Mozambique, even though recent outbreaks were reported in neighboring countries in humans and several cases of RVFV in cattle were reported in several districts in Mozambique.Entities:
Keywords: Arbovirus; Heavy rainfall; Rift valley fever virus; Sub-Saharan Africa
Mesh:
Substances:
Year: 2016 PMID: 27278404 PMCID: PMC4898305 DOI: 10.1186/s12985-016-0542-2
Source DB: PubMed Journal: Virol J ISSN: 1743-422X Impact factor: 4.099
Fig. 1Geographical representation of study area. a shows the geographical localization of Mozambique in south east Africa (Mozambique is highlighted in pink in the small map of Africa) and map of Mozambique (larger map). Coloured districts in Mozambique map, represents districts where cases of RVFV were previously reported in Cattle. b is the representation of the neighborhood of Mavalane health area covered by the Mavalane health center. Mavalane health area comprises two geographical and well delimited areas, namely, Mavalane “A” (yellow) and Mavalane “B” (red) neighborhood
Fig. 2Participant’s recruitment and sample testing. Out of 375 patients recruited, 200 returned to the convalescent visit of which 20 were positive (10.0 %). The corresponding 20 acute samples of those patients were screened using anti-RVFV IgG ELISA. Evidence of seroconversion could be demonstrated in 10 (5.0 %) out of 20 of those patients. Amongst 10 patients who seroconverted for IgG anti-RVFV, only one tested positive the presence of anti-RVFV IgM antibody
Chronological information and laboratory results of the 10 patients with serological evidence of acute RVFV infection
| # | Date of onset of symptoms | Date of blood collection | # days | Seroconversion of anti-RVFV IgG antibodiesa | IgM anti-RVFV in the acute sample | Real- time PCR for RVFV | Malaria blood smear | Anti-malarial treatment |
|---|---|---|---|---|---|---|---|---|
| 1 | Feb 23, 2013 | Feb 24, 2013 | 1 | yes | - | - | - | Yes |
| 2 | Feb 26, 2013 | Feb 27, 2013 | 1 | yes | - | - | - | Yes |
| 3 | Apr 17, 2013 | Apr 18, 2013 | 1 | yes | - | - | - | No |
| 4 | Apr 23, 2013 | Apr 23, 2013 | <1 | yes | - | - | - | Yes |
| 5 | Apr 26, 2013 | Apr 26, 2013 | <1 | yes | - | - | - | Yes |
| 6 | Apr 27, 2013 | Apr 27, 2013 | <1 | yes | - | - | - | No |
| 7 | Apr 27, 2013 | Apr 29, 2013 | 2 | yes | + | - | - | Yes |
| 8 | May 10, 2013 | May 11, 2013 | 1 | yes | - | - | - | NA |
| 9 | May 11, 2013 | May 12, 2013 | 1 | yes | - | - | - | Yes |
| 10 | July 17, 2013 | July 19, 2013 | 2 | yes | - | - | - | No |
#days: between onset disease and sample collection, np not performed, NA not available
aSeroconversion is defined as IgG anti-RVFV level below ELISA cut-off in the acute serum and above ELISA cut-off in convalescent serum
Clinical and demographic characteristics of study participants stratified by RVFV infection status
| Socio-demographic characteristics | Acute RVFV Infection | Previous RVFV exposure | No RVFV antibodies |
|
|---|---|---|---|---|
| n (%) | n (%) | n (%) | ||
| Total |
|
|
| |
| Age | ||||
| Median | 30 | 23 | 28 | 0.202 |
| IQR | 19-42 | 19-30 | 21-35 | |
| Gender | ||||
| Male | 6 (60.0) | 5 (50.0) | 80 (44.4) | 0.603 |
| Female | 4 (40.0) | 5 (50.0) | 100 (55.6) | |
| Recent contact with cattle | 5 (50.0) | 4 (40.0) | 51 (28.3) | 0.136 |
| Recent international travel | 1 (10.0) | 0 | 12 (6.7) | 0.636 |
| Chills | 8 (80.0) | 7 (70.0) | 106 (58.9) | 0.339 |
| Pruritus | 1 (10.0) | 0 | 19 (10.6) | 0.556 |
| Headache | 9 (90.0) | 8 (80.0) | 131 (73.2) | 0.454 |
| Arthralgia | 5 (55.6) | 17 (38.6) | 46 (30.1) | 0.192 |
| Skin Rash | 0 | 1 (10.0) | 47 (8.9) | 0.609 |
| Myalgia | 5 (50.0) | 6 (60.0) | 77 (42.7) | 0.524 |
| Abdominal pain | 6 (60.0) | 7 (70.0) | 81 (45.0) | 0.213 |
| Vomiting | 2 (20.0) | 1 (10.0) | 131 (17.2) | 0.812 |
| Diarrhea | 2 (20.0) | 2 (20.0) | 21 (11.7) | 0.872 |
| Hemorrhage | 0 | 0 | 0 | - |